Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Mallinckrodt
Dow
McKinsey
AstraZeneca

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 7,452,684

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,452,684
Title:Collagen XXII, a novel human collagen and uses thereof
Abstract: The invention provides isolated nucleic acids molecules, designated collagen XXII nucleic acid molecules, which encode a novel collagen. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing collagen XXII nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a collagen XXII gene has been introduced or disrupted. The invention still further provides isolated collagen XXII proteins, fusion proteins, antigenic-peptides and anti-collagen XXII antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Inventor(s): Burgeson; Robert Eugene (Palm Springs, CA), Koch; Manuel (Cambridge, MA), Keene; Douglas R. (Portland, OR), Brunken; William Joseph (Canton, MA), Bruckner-Tuderman; Leena (Munster, DE)
Assignee: The General Hospital Corporation (Boston, MA)
Application Number:11/584,250
Patent Claims:1. An isolated polypeptide comprising an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO:2.

2. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:2.

3. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:2.

4. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:2.

5. The polypeptide of claim 4, wherein the polypeptide is a fusion protein comprising a heterologous amino acid sequence.

6. The polypeptide of claim 4, wherein the polypeptide has one or more of the following activities: (a) has the ability to form a triple helix; (b) has the ability to form collagen fibrils or fibers; (c) binds specifically to an antibody that binds to a polypeptide consisting of residues 28-1626 of SEQ ID NO:2; and (d) is collagenase sensitive.

7. A method of identifying a compound that binds to collagen XXII, the method comprising: contacting the polypeptide of claim 4 with a test compound; and detecting binding of the test compound to the polypeptide, wherein binding of the test compound to the polypeptide indicates that the test compound binds to collagen XXII.

8. The method of claim 7, wherein the contacting is performed in vitro.

9. The method of claim 7, wherein the contacting is performed on a solid surface.

10. The polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

11. The polypeptide of claim 1, wherein the polypeptide is a fusion protein comprising a heterologous amino acid sequence.

12. The polypeptide of claim 1, wherein the polypeptide has one or more of the following activities: (a) has the ability to form a triple helix; (b) has the ability to form collagen fibrils or fibers; (c) binds specifically to an antibody that binds to a polypeptide consisting of residues 28-1626 of SEQ ID NO:2; and (d) is collagenase sensitive.

13. A method of identifying a compound that binds to collagen XXII, the method comprising: contacting the polypeptide of claim 1 with a test compound; and detecting binding of the test compound to the polypeptide, wherein binding of the test compound to the polypeptide indicates that the test compound binds to collagen XXII.

14. The method of claim 13, wherein the contacting is performed in vitro.

15. The method of claim 13, wherein the contacting is performed on a solid surface.

16. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of: (i) residues 28-1004 of SEQ ID NO:2; (ii) residues 1025-1626 of SEQ ID NO:2; (iii) residues 28-1478 of SEQ ID NO:2; (iv) residues 1479-1603 of SEQ ID NO:2; (v) residues 1005-1024 of SEQ ID NO:2; and (v) SEQ ID NO:2 lacking residues 1005-1024.

17. The polypeptide of claim 16, wherein the polypeptide is a fusion protein comprising a heterologous amino acid sequence.

18. An antigenic fragment of SEQ ID NO:2, wherein the fragment comprises at least eight consecutive amino acid residues of SEQ ID NO:2.

19. A method of producing an antibody, the method comprising immunizing an animal with the antigenic fragment of claim 18.

20. The antigenic fragment of claim 18, wherein the fragment comprises at least consecutive amino acid residues of SEQ ID NO:2.

21. The antigenic fragment of claim 18, wherein the fragment comprises at least 15 consecutive amino acid residues of SEQ ID NO:2.

22. The antigenic fragment of claim 18, wherein the fragment comprises at least 20 consecutive amino acid residues of SEQ ID NO:2.

23. The antigenic fragment of claim 18, wherein the fragment comprises at least consecutive amino acid residues of SEQ ID NO:2.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Merck
McKesson
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.